Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
BPH GlobalASX:BP8DF -50.00% Days Sales Outstanding is 50.44 as of Jun. 2026, which is 18% below its 10-year median of 61.72. The stock has 6 warning signs investors should review. Among 947 Drug Manufacturers companies, BPH Global ranks better than 76.98% on this metric.
BPH Global's average Accounts Receivable for the
six
months ended in Jun. 2026 was A$0.57 Mil. BPH Global's Revenue for the
six
months ended in Jun. 2026 was A$2.07 Mil.
Hence, BPH Global's Days Sales Outstanding for the
six
months ended in Jun. 2026 was 50.44.
The historical rank and industry rank for BPH Global's Days Sales Outstanding or its related term are showing as below:
ASX:BP8DF'
s Days Sales Outstanding Range Over the Past 10 Years
Min: 16.72 Med: 61.72 Max: 185.61
Current: 47.22
During the past 13 years, BPH Global's highest Days Sales Outstanding was 185.61. The lowest was 16.72. And the median was 61.72.
ASX:BP8DF's Days Sales Outstanding is ranked better than 76.98% of 947
companies
in the Drug Manufacturers industry
Industry Median: 71.98
vs ASX:BP8DF: 47.22
BPH Global's Days Sales Outstanding
declined
from Jun. 2025 (108.10) to Jun. 2026 (50.44).
BPH Global (ASX:BP8DF) Days Sales Outstanding Explanation
For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.
BPH Global Days Sales Outstanding Related Terms
BPH Global Days Sales Outstanding Historical Data
* Premium members only.
The historical data trend for BPH Global's Days Sales Outstanding can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ASX:BP8DF vs ZTS, UTHR: Days Sales Outstanding Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, BPH Global's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BPH Global Days Sales Outstanding vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, BPH Global's Days Sales Outstanding distribution charts can be found below:
* The bar in red indicates where BPH Global's Days Sales Outstanding falls into.
Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BPH Global (ASX:BP8DF) has a Days Sales Outstanding of 50.44 as of Jun. 2026. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on BPH Global and its competitors. This is 18% below median its historical median of 61.72. Over the past decade, BPH Global's Days Sales Outstanding has ranged from 16.72 to 185.61. According to the industry distribution chart, BPH Global ranks #218 out of 947 companies in the Drug Manufacturers industry, placing it in the top 23%.
Is BPH Global's Days Sales Outstanding too high?
BPH Global's current Days Sales Outstanding of 50.44 is 18% below median its 10-year median of 61.72. Over the past 10 years, this metric has ranged from a low of 16.72 to a high of 185.61. The Drug Manufacturers industry median Days Sales Outstanding is 71.98. BPH Global's value of 50.44 is 29.9% below this industry median. Based on the distribution chart, BPH Global ranks #218 out of 947 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers.
How does BPH Global's Days Sales Outstanding compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, BPH Global ranks #218 out of 947 companies for Days Sales Outstanding. This places BPH Global in the top 23% of its industry — outperforming the majority of peers. The industry median Days Sales Outstanding is 71.98. BPH Global's value of 50.44 is 29.9% below this benchmark. Historically, BPH Global's own Days Sales Outstanding has ranged from 16.72 to 185.61 over the past decade. While the company's 10-year median is 61.72 vs. the industry median of 71.98, BPH Global has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Sales Outstanding for a Drug Manufacturers company?
The median Days Sales Outstanding among Drug Manufacturers companies is 71.98, based on 947 companies in the industry. Companies in the top quartile (top 25%) have a Days Sales Outstanding significantly above this median, while those in the bottom quartile fall well below. However, Days Sales Outstanding should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. BPH Global's current Days Sales Outstanding of 50.44 is 29.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Sales Outstanding mean?
A high Days Sales Outstanding can signal that a stock is expensive relative to its fundamentals. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on BPH Global and its competitors. For the Drug Manufacturers industry, the median Days Sales Outstanding is 71.98 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. BPH Global's current Days Sales Outstanding is 50.44, which is 18% below median its own 10-year median of 61.72. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BPH Global stock overvalued right now?
BPH Global (ASX:BP8DF) has a current Days Sales Outstanding of 50.44. The current Days Sales Outstanding is 50.44, which is 18% below median its 10-year median of 61.72 and 29.9% below the Drug Manufacturers industry median of 71.98. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Sales Outstanding calculated?
Days Sales Outstanding is calculated from a company's financial statements. For BPH Global (ASX:BP8DF), the current Days Sales Outstanding is 50.44 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
BPH Global Ltd is a plant-focused biotechnology company with a focus on producing foods, health, and cosmetic products that deliver Traditional Chinese Medicine (TCM)-based health outcomes. It focuses on the research, development, production, and commercialization of TCM products, including bird's nest, seaweeds, and sea plants, which serve as sustainable plant-based protein sources and ingredients for food, nutrition, healthcare, cosmetics, and personal care industries. The company's geographical segment includes Australia, Indonesia, and China. The company's products comprise raw and processed bird's nest, sea grapes (Caulerpa lentillifera), and other seaweeds and sea plants.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:BP8DF has been successfully added to your 
